Role of tumour necrosis factor gene polymorphisms (-308 and -238) in breast cancer susceptibility and severity

Breast Cancer Research

Malcolm WR Reed³  Nicola J Brown³  Angela Cox⁴  Timothy J Stephenson¹  Anthony G Wilson²  Saba P Balasubramanian³  Iman AF Azmy³ 

[1] Department of Histopathology, University of Sheffield, UK;Academic Rheumatology Unit, University of Sheffield, UK;Academic Surgical Oncology Unit, University of Sheffield, UK;Institute of Cancer Studies, University of Sheffield, UK

关键词: vascular invasion;    tumour necrosis factor;    genetic polymorphisms;    breast cancer;   

Others  :  1118741
DOI  :  10.1186/bcr802

 received in 2003-12-07, accepted in 2004-04-26,  发布年份 2004

【 摘 要 】

Introduction

Genetic polymorphisms in the promoter region of the tumour necrosis factor (TNF) gene can regulate gene expression and have been associated with inflammatory and malignant conditions. We have investigated two polymorphisms in the promoter of the TNF gene (-308 G>A and -238 G>A) for their role in breast cancer susceptibility and severity by means of an allelic association study.

Methods

Using a case–control study design, breast cancer patients (n = 709) and appropriate age-matched and sex-matched controls obtained from the Breast Screening Unit (n = 498) were genotyped for these TNF polymorphisms, using a high-throughput allelic discrimination method.

Results

Allele frequencies for both polymorphisms were similar in both breast cancer cases and controls. However, the -308 polymorphism was found to be associated with vascular invasion in breast tumours (P = 0.024). Comparison with other standard prognostic indices did not show any association for either genotype.

Conclusions

We demonstrated no association between the -308G>A polymorphism and the -238G>A polymorphism in the promoter region of TNF and susceptibility to breast cancer, in a large North European population. However, the -308 G>A polymorphism was found to be associated with the presence of vascular invasion in breast tumours.

【 授权许可】

   
2004 Azmy et al.; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

【 参考文献 】

• [1]Greene MH: Genetics of breast cancer. Mayo Clin Proc 1997, 72:54-65.
• [2]Dunning AM, Healey CS, Pharoah PD, Teare MD, Ponder BA, Easton DF: A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1999, 8:843-854.
• [3]Coughlin SS, Piper M: Genetic polymorphisms and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 1999, 8:1023-1032.
• [4]Weber BL, Nathanson KL: Low penetrance genes associated with increased risk for breast cancer. Eur J Cancer 2000, 36:1193-1199.
• [5]Bazzoni F, Beutler B: The tumor necrosis factor ligand and receptor families. N Engl J Med 1996, 334:1717-1725.
• [6]Beutler B, Cerami A: The biology of cachectin/TNF – a primary mediator of the host response. Annu Rev Immunol 1989, 7:625-655.
• [7]Jaattela M: Biologic activities and mechanisms of action of tumor necrosis factor-alpha/cachectin. Lab Invest 1991, 64:724-742.
• [8]Komori A, Yatsunami J, Suganuma M, Okabe S, Abe S, Sakai A, Sasaki K, Fujiki H: Tumor necrosis factor acts as a tumor promoter in BALB/3T3 cell transformation. Cancer Res 1993, 53:1982-1985.
• [9]Fujiki H, Suganuma M: Tumor necrosis factor-alpha, a new tumor promoter, engendered by biochemical studies of okadaic acid. J Biochem (Tokyo) 1994, 115:1-5.
• [10]Fujiki H, Suganuma M, Komori A, Yatsunami J, Okabe S, Ohta T, Sueoka E: A new tumor promotion pathway and its inhibitors. Cancer Detect Prev 1994, 18:1-7.
• [11]Suganuma M, Okabe S, Marino MW, Sakai A, Sueoka E, Fujiki H: Essential role of tumor necrosis factor alpha (TNF-alpha) in tumor promotion as revealed by TNF-alpha-deficient mice. Cancer Res 1999, 59:4516-4518.
• [12]Warzocha K, Salles G, Bienvenu J, Bastion Y, Dumontet C, Renard N, Neidhardt-Berard EM, Coiffier B: Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients. J Clin Oncol 1997, 15:499-508.
• [13]Nakashima J, Tachibana M, Ueno M, Miyajima A, Baba S, Murai M: Association between tumor necrosis factor in serum and cachexia in patients with prostate cancer. Clin Cancer Res 1998, 4:1743-1748.
• [14]Leek RD, Landers R, Fox SB, Ng F, Harris AL, Lewis CE: Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma. Br J Cancer 1998, 77:2246-2251.
• [15]Ioculano M, Altavilla D, Squadrito F, Canale P, Squadrito G, Saitta A, Campo GM, Caputi AP: Tumour necrosis factor mediates E-selectin production and leukocyte accumulation in myocardial ischaemia-reperfusion injury. Pharmacol Res 1995, 31:281-288.
• [16]Hajeer AH, Hutchinson IV: Influence of TNFalpha gene polymorphisms on TNFalpha production and disease. Hum Immunol 2001, 62:1191-1199.
• [17]Bouma G, Xia B, Crusius JB, Bioque G, Koutroubakis I, Von Blomberg BM, Meuwissen SG, Pena AS: Distribution of four polymorphisms in the tumour necrosis factor (TNF) genes in patients with inflammatory bowel disease (IBD). Clin Exp Immunol 1996, 103:391-396.
• [18]Louis E, Franchimont D, Piron A, Gevaert Y, Schaaf-Lafontaine N, Roland S, Mahieu P, Malaise M, De Groote D, Louis R, Belaiche J: Tumour necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 1998, 113:401-406.
• [19]Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW: Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 1997, 94:3195-3199.
• [20]Huizinga TW, Westendorp RG, Bollen EL, Keijsers V, Brinkman BM, Langermans JA, Breedveld FC, Verweij CL, van de Gaer L, Dams L, Crusius JB, Garcia-Gonzalez A, van Oosten BW, Polman CH, Pena AS: TNF-alpha promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients. J Neuroimmunol 1997, 72:149-153.
• [21]Chouchane L, Ahmed SB, Baccouche S, Remadi S: Polymorphism in the tumor necrosis factor-alpha promotor region and in the heat shock protein 70 genes associated with malignant tumors. Cancer 1997, 80:1489-1496.
• [22]Mestiri S, Bouaouina N, Ahmed SB, Khedhaier A, Jrad BB, Remadi S, Chouchane L: Genetic variation in the tumor necrosis factor-alpha promoter region and in the stress protein hsp70-2: susceptibility and prognostic implications in breast carcinoma. Cancer 2001, 91:672-678.
• [23]Park KS, Mok JW, Ko HE, Tokunaga K, Lee MH: Polymorphisms of tumour necrosis factors A and B in breast cancer. Eur J Immunogenet 2002, 29:7-10.
• [24]Jang WH, Yang YI, Yea SS, Lee YJ, Chun JH, Kim HI, Kim MS, Paik KH: The -238 tumor necrosis factor-alpha promoter polymorphism is associated with decreased susceptibility to cancers. Cancer Lett 2001, 166:41-46.
• [25]di Giovine FS, Camp NJ, Cox A, Chaudhary AG, Sorrell JA, Crane A, Duff GW: Detection and Population Analysis of IL-1 and TNF Gene Polymorphisms. Oxford: Oxford University Press; 2000.
• [26]Daly AK, Day CP: Candidate gene case–control association studies: advantages and potential pitfalls. Br J Clin Pharmacol 2001, 52:489-499.
• [27]Perneger TV: What's wrong with Bonferroni adjustments. Br Med J 1998, 316:1236-1238.
• [28]Yoshida S, Ono M, Shono T, Izumi H, Ishibashi T, Suzuki H, Kuwano M: Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol 1997, 17:4015-4023.
• [29]Philp EA, Stephenson TJ, Reed MW: Prognostic significance of angiogenesis in transitional cell carcinoma of the human urinary bladder. Br J Urol 1996, 77:352-357.
• [30]Balkwill F: Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev 2002, 13:135-141.
• [31]Malik ST, Griffin DB, Fiers W, Balkwill FR: Paradoxical effects of tumour necrosis factor in experimental ovarian cancer. Int J Cancer 1989, 44:918-925.
• [32]Malik ST, Naylor MS, East N, Oliff A, Balkwill FR: Cells secreting tumour necrosis factor show enhanced metastasis in nude mice. Eur J Cancer 1990, 26:1031-1034.
• [33]Okahara H, Yagita H, Miyake K, Okumura K: Involvement of very late activation antigen 4 (VLA-4) and vascular cell adhesion molecule 1 (VCAM-1) in tumor necrosis factor alpha enhancement of experimental metastasis. Cancer Res 1994, 54:3233-3236.
• [34]Orosz P, Kruger A, Hubbe M, Ruschoff J, Von Hoegen P, Mannel DN: Promotion of experimental liver metastasis by tumor necrosis factor. Int J Cancer 1995, 60:867-871.
• [35]Balasubramanian SP, Brown NJ, Reed MW: Role of genetic polymorphisms in tumour angiogenesis. Br J Cancer 2002, 87:1057-1065.
• [36]Balasubramanian SP, Cox A, Wilson AG, Brown NJ, Reed MW: Endostatin polymorphism in breast cancer. Eur J Surg Oncol 2002, 28:786 [Abstract].